Operating Segments

3 Months Ended

Mar. 31, 2014

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended March 31,
	2014			2013
Contract/Grant Revenue
Vaccines/BioDefense	$	877,045		$	829,849
BioTherapeutics		33,552			70,505
Total	$	910,597		$	900,354
Income/(Loss) from Operations
Vaccines/BioDefense	$	139,404		$	(30,995	)
BioTherapeutics		(1,035,591	)		(457,625	)
Corporate		(693,722	)		(599,277	)
Total	$	(1,589,909	)	$	(1,087,897	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,935		$	27,667
BioTherapeutics		49,939			28,395
Corporate		2,213			436
Total	$	62,087		$	56,498
Interest Income
Corporate	$	291		$	483
Stock-Based Compensation
Vaccines/BioDefense	$	10,450		$	11,121
BioTherapeutics		76,121			21,036
Corporate		90,091			47,335
Total	$	176,662		$	79,492

	As of March 31,  2014		As of December 31, 2013
Identifiable Assets
Vaccines/BioDefense	$	948,567	$	1,870,414
BioTherapeutics		339,502		386,721
Corporate		5,724,904		6,008,320
Total	$	7,012,973	$	8,265,455